Please login to the form below

Not currently logged in

Bentley wins US intranasal technology patent protection

Bentley Pharmaceuticals has revealed that the US Patent and Trademark Office issued it with patent protection on its intranasal technology

US-based specialty pharmaceutical company, Bentley Pharmaceuticals, has received US Patent and Trademark Office recognition through the award of patent number 7,244,703 entitled "Pharmaceutical Compositions and Methods for Peptide Treatment."

The patent extends coverage for Bentley's current intranasal drug delivery technology employing CPE-215 beyond insulin to include delivery of other therapeutically effective, pharmaceutically active peptides, peptidomimetics and proteins.

In September 2006, Bentley received a US patent covering its intranasal delivery spray for insulin.

The new patent, which was issued from an application filed back in 2004, provides proprietary protection to Bentley for 20 years from the date of filing.

23rd July 2007


Featured jobs

Subscribe to our email news alerts


Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...